Proteomic analysis of inhibitor of apoptosis protein‑like protein‑2 on breast cancer cell proliferation

Xiang,Siqi; Zhu,Lin; Zhang,Zhiliang; Wang,Siyuan; Cui,Ruxia; Xiang,Mingjun

doi:10.3892/mmr.2022.12605

Proteomic analysis of inhibitor of apoptosis protein‑like protein‑2 on breast cancer cell proliferation

Authors:
- Siqi Xiang
- Lin Zhu
- Zhiliang Zhang
- Siyuan Wang
- Ruxia Cui
- Mingjun Xiang
View Affiliations

Affiliations: Department of Biochemistry and Immunology, Medical Research Center, Institute of Medicine, Jishou University, Jishou, Hunan 416000, P.R. China
Published online on: January 17, 2022 https://doi.org/10.3892/mmr.2022.12605
Article Number: 89
Copyright: © Xiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although inhibitor of apoptosis protein‑like protein‑2 (ILP‑2) is considered to be a novel enhancer of breast cancer proliferation, its underlying mechanism of action remains unknown. Therefore, the present study aimed to investigate the expression profile of ILP‑2‑related proteins in MCF‑7 cells to reveal their effect on promoting breast cancer cell proliferation. The isobaric tags for relative and absolute quantification (iTRAQ) method was used to analyse the expression profile of ILP‑2‑related proteins in MCF‑7 breast cancer cells transfected with small interfering (si)RNA against ILP‑2 (siRNA‑5 group) and the negative control (NC) siRNA. The analysis of the iTRAQ data was carried out using western blotting and reverse transcription‑quantitative PCR. A total of 4,065 proteins were identified in MCF‑7 cells, including 241 differentially expressed proteins (DEPs; fold change ≥1.20 or ≤0.83; P<0.05). Among them, 156 proteins were upregulated and 85 were downregulated in the siRNA‑5 group compared with in the NC group. The aforementioned DEPs were mainly enriched in ‘ECM‑receptor interaction’. In addition, the top 10 biological processes related to these proteins were associated with signal transduction, cell proliferation and immune system processes. Furthermore, ILP‑2 silencing upregulated N(4)‑(β‑N‑acetylglucosaminyl)‑L‑asparaginase, metallothionein‑1E and tryptophan 2,3‑dioxygenase, whereas ILP‑2 overexpression exerted the opposite effect. The results of the present study suggested that ILP‑2 could promote breast cancer growth via regulating cell proliferation, signal transduction, immune system processes and other cellular physiological activities.

View Figures

View References

1	Kimball CC, Nichols CI and Vose JG: The payer and patient cost burden of open breast conserving procedures following percutaneous breast biopsy. Breast Cancer (Auckl). 12:11782234187777662018.PubMed/NCBI
2	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
3	Al-Darwish AA, Al-Naim AF, Al-Mulhim KS, Al-Otaibi NK, Morsi MS and Aleem AM: Knowledge about cervical cancer early warning signs and symptoms, risk factors and vaccination among students at a medical school in Al-Ahsa, Kingdom of Saudi Arabia. Asian Pac J Cancer Prev. 15:2529–2532. 2014. View Article : Google Scholar : PubMed/NCBI
4	Thomas KH and Ramirez RA: Leptomeningeal disease and the evolving role of molecular targeted therapy and immunotherapy. Ochsner J. 17:362–378. 2017.PubMed/NCBI
5	Costa RLB, Han HS and Gradishar WJ: Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: A review. Breast Cancer Res Treat. 169:397–406. 2018. View Article : Google Scholar : PubMed/NCBI
6	Qing L and Qing W: Development of epidermal growth factor receptor targeted therapy in pancreatic cancer. Minerva Chir. 73:488–496. 2018. View Article : Google Scholar : PubMed/NCBI
7	Zhu L, Zhou W, Zhu X, Xiang S, Wang S, Peng Y, Lu B, Tang P, Chen Q, Wu M, et al: Inhibitor of apoptosis protein-like protein-2: A novel growth accelerator for breast cancer cells. Oncol Rep. 40:2047–2055. 2018.PubMed/NCBI
8	Xiang M, Zhou W, Gao D, Fang X and Liu Q: Inhibitor of apoptosis protein-like protein-2 as a novel serological biomarker for breast cancer. Int J Mol Sci. 13:16737–16750. 2012. View Article : Google Scholar : PubMed/NCBI
9	Ouyang H, Wang Z, Chen X, Yu J, Li Z and Nie Q: Proteomic analysis of chicken skeletal muscle during embryonic development. Front Physiol. 8:2812017. View Article : Google Scholar : PubMed/NCBI
10	Campos JM, Neves LX, de Paiva NC, de Oliveira E Castro RA, Casé AH, Carneiro CM, Andrade MH and Castro-Borges W: Understanding global changes of the liver proteome during murine schistosomiasis using a label-free shotgun approach. J Proteomics. 151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
11	Liu J, Liu Z, Chen L and Zhang H: iTRAQ-based proteomic analysis reveals alterations in the liver induced by restricted meal frequency in a pig model. Nutrition. 32:871–876. 2016. View Article : Google Scholar : PubMed/NCBI
12	Minjarez B, Calderón-González KG, Rustarazo ML, Herrera-Aguirre ME, Labra-Barrios ML, Rincon-Limas DE, Del Pino MM, Mena R and Luna-Arias JP: Identification of proteins that are differentially expressed in brains with Alzheimer's disease using iTRAQ labeling and tandem mass spectrometry. J Proteomics. 139:103–121. 2016. View Article : Google Scholar : PubMed/NCBI
13	Liu YC, Ma WH, Ge YL, Xue ML, Zhang Z, Zhang JY, Hou L and Mu RH: RNAi-mediated gene silencing of vascular endothelial growth factor C suppresses growth and induces apoptosis in mouse breast cancer in vitro and in vivo. Oncol Lett. 12:3896–3904. 2016. View Article : Google Scholar : PubMed/NCBI
14	Yan F, Wang X, Zhu M and Hu X: RNAi-mediated downregulation of cyclin Y to attenuate human breast cancer cell growth. Oncol Rep. 36:2793–2799. 2016. View Article : Google Scholar : PubMed/NCBI
15	Wang X, Li Y, Xu G, Liu M, Xue L, Liu L, Hu S, Zhang Y, Nie Y, Liang S, et al: Mechanism study of peptide GMBP1 and its receptor GRP78 in modulating gastric cancer MDR by iTRAQ-based proteomic analysis. BMC Cancer. 15:3582015. View Article : Google Scholar : PubMed/NCBI
16	Lu ZM, Zhu Q, Li HX, Geng Y, Shi JS and Xu ZH: Vanillin promotes the germination of antrodia camphorata arthroconidia through PKA and MAPK signaling pathways. Front Microbiol. 8:20482017. View Article : Google Scholar : PubMed/NCBI
17	Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, et al: STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43:(Database Issue). D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Ju J, Zhu AJ and Yuan P: Progress in targeted therapy for breast cancer. Chronic Dis Transl Med. 4:164–175. 2018.PubMed/NCBI
20	Jitariu AA, Raica M, Cîmpean AM and Suciu SC: The role of PDGF-B/PDGFR-BETA axis in the normal development and carcinogenesis of the breast. Crit Rev Oncol Hematol. 131:46–52. 2018. View Article : Google Scholar : PubMed/NCBI
21	Zoi I, Karamouzis MV, Adamopoulos C and Papavassiliou AG: RANKL signaling and ErbB receptors in breast carcinogenesis. Trends Mol Med. 22:839–850. 2016. View Article : Google Scholar : PubMed/NCBI
22	Jana S, Sengupta S, Biswas S, Chatterjee A, Roy H and Bhattacharyya A: miR-216b suppresses breast cancer growth and metastasis by targeting SDCBP. Biochem Biophys Res Commun. 482:126–133. 2017. View Article : Google Scholar : PubMed/NCBI
23	Wang Y, Zhou J, Wang Z, Wang P and Li S: Upregulation of SOX2 activated LncRNA PVT1 expression promotes breast cancer cell growth and invasion. Biochem Biophys Res Commun. 493:429–436. 2017. View Article : Google Scholar : PubMed/NCBI
24	Stricker TP, Brown CD, Bandlamudi C, McNerney M, Kittler R, Montoya V, Peterson A, Grossman R and White KP: Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression. PLoS Genet. 13:e10065892017. View Article : Google Scholar : PubMed/NCBI
25	Shi Y, Yang F, Sun Z, Zhang W, Gu J and Guan X: Differential microRNA expression is associated with androgen receptor expression in breast cancer. Mol Med Rep. 15:29–36. 2017. View Article : Google Scholar : PubMed/NCBI
26	Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al: PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11:R772009. View Article : Google Scholar : PubMed/NCBI
27	Stavik B, Skretting G, Olstad OK, Sletten M, Dehli Vigeland M, Sandset PM and Iversen N: TFPI alpha and beta regulate mRNAs and microRNAs involved in cancer biology and in the immune system in breast cancer cells. PLoS One. 7:e47184. 2012. View Article : Google Scholar : PubMed/NCBI
28	Vences-Catalán F, Duault C, Kuo CC, Rajapaksa R, Levy R and Levy S: CD81 as a tumor target. Biochem Soc Trans. 45:531–535. 2017. View Article : Google Scholar : PubMed/NCBI
29	Gurel V, Sens DA, Somji S, Garrett SH, Weiland T and Sens MA: Post-transcriptional regulation of metallothionein isoform 1 and 2 expression in the human breast and the MCF-10A cell line. Toxicol Sci. 85:906–915. 2005. View Article : Google Scholar : PubMed/NCBI
30	Tai SK, Tan OJ, Chow VT, Jin R, Jones JL, Tan PH, Jayasurya A and Bay BH: Differential expression of metallothionein 1 and 2 isoforms in breast cancer lines with different invasive potential: Identification of a novel nonsilent metallothionein-1H mutant variant. Am J Pathol. 163:2009–2019. 2003. View Article : Google Scholar : PubMed/NCBI
31	Novikov O, Wang Z, Stanford EA, Parks AJ, Ramirez-Cardenas A, Landesman E, Laklouk I, Sarita-Reyes C, Gusenleitner D, Li A, et al: An Aryl hydrocarbon receptor-mediated amplification loop that enforces cell migration in ER-/PR-/Her2-human breast cancer cells. Mol Pharmacol. 90:674–688. 2016. View Article : Google Scholar : PubMed/NCBI
32	D'Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra NS, Nemkov TG, D'Alessandro A, Hansen KC and Richer JK: A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. Cancer Res. 75:4651–4664. 2015. View Article : Google Scholar : PubMed/NCBI
33	Saarela J, von Schantz C, Peltonen L and Jalanko A: A novel aspartylglucosaminuria mutation affects translocation of aspartylglucosaminidase. Hum Mutat. 24:350–351. 2004. View Article : Google Scholar : PubMed/NCBI
34	Saarela J, Oinonen C, Jalanko A, Rouvinen J and Peltonen L: Autoproteolytic activation of human aspartylglucosaminidase. Biochem J. 378:363–371. 2004. View Article : Google Scholar : PubMed/NCBI